Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Fulcrum Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FULC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: FULC's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: FULC underperformed the US Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: FULC underperformed the US Market which returned 52.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Fulcrum Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StWe're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely
1 month ago | Simply Wall StFulcrum Therapeutics' (NASDAQ:FULC) Stock Price Has Reduced 15% In The Past Year
3 months ago | Simply Wall StCould The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Ownership Structure Tell Us Something Useful?
Is Fulcrum Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FULC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FULC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FULC is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: FULC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FULC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FULC is good value based on its PB Ratio (2.7x) compared to the US Pharmaceuticals industry average (3.7x).
How is Fulcrum Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FULC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FULC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FULC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FULC's revenue (56.6% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: FULC's revenue (56.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FULC is forecast to be unprofitable in 3 years.
How has Fulcrum Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FULC is currently unprofitable.
Growing Profit Margin: FULC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FULC is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare FULC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FULC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.1%).
Return on Equity
High ROE: FULC has a negative Return on Equity (-54.3%), as it is currently unprofitable.
How is Fulcrum Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: FULC's short term assets ($147.0M) exceed its short term liabilities ($22.6M).
Long Term Liabilities: FULC's short term assets ($147.0M) exceed its long term liabilities ($6.1M).
Debt to Equity History and Analysis
Debt Level: FULC is debt free.
Reducing Debt: FULC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FULC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FULC has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 23.2% each year.
What is Fulcrum Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FULC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FULC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FULC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FULC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FULC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bryan Stuart (44 yo)
Mr. Bryan E. Stuart serves as President, Chief Executive Officer and Director at Fulcrum Therapeutics, Inc., since March 31, 2021. He had been Chief Operating Officer of Fulcrum Therapeutics, Inc., since D...
CEO Compensation Analysis
Compensation vs Market: Bryan's total compensation ($USD1.23M) is about average for companies of similar size in the US market ($USD1.71M).
Compensation vs Earnings: Bryan's compensation has been consistent with company performance over the past year.
Experienced Management: FULC's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: FULC's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.5%.
Fulcrum Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Fulcrum Therapeutics, Inc.
- Ticker: FULC
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$327.795m
- Shares outstanding: 32.55m
- Website: https://www.fulcrumtx.com
Number of Employees
- Fulcrum Therapeutics, Inc.
- 26 Landsdowne Street
- United States
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medic...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/06 23:18|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.